Aim: To confirm the observed reduction in HbA1c for the 2.5 mg dose in EASE-3 by modelling and simulation analyses.
| INTRODUCTION
Sodium-glucose co-transporter-2 (SGLT-2) inhibitors have been proven to be effective for metabolic control and for the prevention of cardiovascular and renal outcomes in patients with type 2 diabetes, [1] [2] [3] and have also been extensively tested as adjunct-to-insulin therapy in patients with type 1 diabetes as a promising glucose-lowering strategy. Seven phase 3 randomized clinical trials from three clinical development programmes in patients with type 1 diabetes have been completed with SGLT-2 inhibitors: three with sotagliflozin, 4-6 two with dapagliflozin 7, 8 and two with empagliflozin. 9 Collectively, these trials showed consistent HbA1c lowering (mean 0.3%-0.5%) and improvements in "time in range" on continuous glucose monitoring measures without an increase in hypoglycaemia, as well as body weight and systolic blood pressure reductions. 10 A clear dose-dependent causal relationship with the incidence of diabetic ketoacidosis (DKA), however, has been observed in all programmes. Of seven trials, only one (EASE-3) tested a lower dose than those approved for type 2 diabetes to minimize the risk of DKA and still achieved valuable efficacy data. 9 EASE-3 included a low-dose empagliflozin 2.5 mg arm together with the 10 and 25 mg orally once-daily arms and showed significant gluco-metabolic benefits with the low dose, although slightly lower in magnitude than those observed with higher doses, without an increased risk of DKA. 9 Lower doses than used in type 2 diabetes were not studied in the sotagliflozin or dapagliflozin programmes for patients with type 1 diabetes.
Based on indirect pharmacodynamic (PD) comparisons, the lowdose SGLT-2 inhibitor approach is supported by findings from a dosefinding study in which the magnitude of urinary glucose excretion associated with 2.5 mg empagliflozin in patients with type 1 diabetes exceeded that observed at the 10 and 25 mg doses observed in patients with type 2 diabetes. 11 Traditionally, two phase 3 trials are required for regulatory approval. However, even though two phase 3 trials of empagliflozin were conducted, only one included the 2.5 mg empagliflozin dose. We therefore sought validated and well-established modelling and simulation techniques to characterize drug exposure and clinical endpoint response relationships in empagliflozin trials that were independent from the phase 3 trial that directly tested the low dose. Although such model-informed drug discovery and development (MID3) should not replace all clinical trials, in this particular situation, where efficacy and safety have been established across a wide, clinically relevant dose range, such an approach is supported by health authorities. 12, 13 We aimed to determine the 26-and 52-week efficacy of empagliflozin 2.5 mg/day in HbA1c lowering by conducting two exposure-response modelling analyses, which were based on individual patient-level data, each using exposure data from two trials (EASE-1 11 and EASE-2 9 ).
SGLT-2 inhibitors are known to increase circulating ketone levels. As increased beta-hydroxybutyrate (BHB) levels in the presence of predisposing and precipitating factors such as non-adherence, insulin restriction/omission and disordered eating behaviours may be an indicator of DKA risk, 14 a similar analysis to evaluate the impact of empagliflozin exposure on changes in BHB levels was conducted.
| MATERIALS AND METHODS

| Population pharmacokinetic modelling to derive individual empagliflozin exposure data
To understand the exposure (concentrations) of empagliflozin from administration until complete elimination from circulation (the PK profile), a population PK analysis was conducted based on a previous model. 15 This analysis was performed on the 1241 patients with type 1 diabetes exposed to empagliflozin (excluding the placebo-assigned participants) in the 28-day EASE-1 phase 2 trial, 11 the 26-week EASE-3 phase 3 trial 9 and the 52-week EASE-2 phase 3 trial. 9 Modelling was based on 6880 plasma concentration measurements with up to and other patient-specific factors including renal function and insulin delivery (multiple daily injections or insulin pump). Exposure-response was described by maximum effect (Emax) models for total daily insulin dose and mean daily glucose. Changes in mean daily glucose drove changes in HbA1c, which were linked by a linear model. We simulated the changes in HbA1c assuming that empagliflozin therapy leads to a decrease in total daily insulin dose as observed in our trials, but we also simulated the changes in HbA1c, assuming the patients made no adjustments in their insulin doses. 16 2.3 | The M-EASE-2 (descriptive) model: determination of the 26-and 52-week exposureresponse relationship for low-dose empagliflozin in the EASE-2 population
The aim of this analysis was to simulate the effect of empagliflozin 2.5 mg over 26 and 52 weeks of treatment in the EASE-2 study population and to confirm the observed effect on HbA1c at this dose seen in EASE-3. It followed a descriptive modelling approach predicting longitudinal changes in HbA1c from the individual AUCτ,ss derived from the population PK model. 17 To enable predictions for the low dose of empagliflozin, the AUC 50 (AUCτ,ss resulting in the halfmaximal effect of an exposure-response relation) from an exposureresponse analysis in patients with type 2 diabetes was used to characterize the exposure-response in patients with type 1 diabetes. 18, 19 This assumption was evaluated by sensitivity analyses and further supported by the comparable exposure-response for urinary glucose excretion in the two patient populations. 15 Mean daily glucose was not included in the model.
| Clinical verification of modelling and simulation approaches
Both modelling approaches were verified by clinical trial simulations using baseline characteristics and study design from the EASE-3 trial.
This trial, which included an empagliflozin 2.5 mg dose arm, was not used during model development and hence served as an independent comparator. 16, 17 In addition to comparing simulated mean change from baseline in Investigation of covariates was performed following a full modelling approach. Covariates (Table S1) were selected based on known relations from patients with type 2 diabetes (eg, estimated glomerular filtration rate, weight and sex) and type 1 diabetes specific factors (eg, total daily insulin dose and insulin dose type). Table 1 summarizes the previously published empiric placeboadjusted HbA1c projected findings for empagliflozin 2.5 mg from the EASE-1 and EASE-3 studies at 28 days and 26 weeks, respectively, including the empagliflozin 2.5 mg dose ( Table 2 , Figures S1 and S2) , thereby confirming the adequacy of using the models to simulate untested scenarios.
| Statistical analyses
| RESULTS
The population PK model predictions adequately described the observed concentrations both after the first dose and at steady state ( Figure S3 ). Evaluation of the model showed its ability to predict patient drug exposures at steady state. Variability in AUCτ,ss was primarily affected by renal function, female sex, smoking status and weight, although all of these covariate influences on AUCτ,ss were of minor magnitude ( Figure S4 ).
The analysis of BHB levels showed a clear exposure-response elevation; however, the increase in BHB was of low magnitude. Median Figure S5 ), and with a median BHB of 0.110 mmol/L at baseline, the overall increase was substantially below the cut-off used to identify ketosis events (1.5 mmol/L).
| DISCUSSION
Using a large PK database to derive drug exposure combined with the baseline characteristics and outcome measures from the type 1 diabetes empagliflozin clinical trial programme, we were able to determine that the directly observed 26-week mean placebo-corrected HbA1c reduction of −0.28% from baseline in the empagliflozin 2.5 mg arm of the EASE-3 trial was confirmed to be similar in two independent modelling and simulation studies. Specifically, the HbA1c change according to these models was −0.29% at 26 weeks, sustained over 52 weeks, and greater with higher baseline HbA1c. The approach predicted that greater efficacy could be achieved on a stable insulin dose compared with one in which insulin dose was adjusted at the initiation of empagliflozin treatment.
While, in retrospect, the full phase 3 SGLT-2 inhibitor clinical trial programmes for type 1 diabetes could have investigated lower type 1 diabetes-specific effective doses to minimize DKA risk, such an approach was assessed only in one trial within the empagliflozin phase 3 programme, in addition to the evaluation in the phase 2 trial (EASE-1). 9 Traditionally, two phase 3 trials are required for regulatory approval. However, the US Food and Drug Administration (FDA) Modernization Act permits the determination of effectiveness to be based on "data from one adequate and well-controlled investigation and confirmatory evidence". 13 The FDA has also provided guidance on exposure-response relationships that states, "Exposure-response studies can support, or in some cases provide primary evidence for the approval of different doses" of pharmacotherapies that have been investigated at different doses in controlled clinical trials to contribute to existing evidence for substantial efficacy. 13, 21, 22 The phase 3 clinical trial programme for empagliflozin, in particular, lends itself very well to the generation of model-informed supportive evidence.
Although the model-informed approach is an accepted method to confirm findings from a clinical trial, there are limitations. First, while the modelling results show the expected efficacy from the clinical trial study population, these results may not be generalizable to the type 1 diabetes general population. Second, assumptions about AUC 50 in one of the models were conservatively derived from type 2 diabetes studies. The comparability of the exposure-response in patients with type 1 diabetes and type 2 diabetes was previously assessed. 15 Although the maximal urinary glucose excretion was greater in patients with type 1 diabetes compared with patients with type 2 diabetes, the general shape of that exposure-response curve, and importantly its inflection point (AUC 50 ), was very similar between the two patient populations. 15 This assumption was assessed during sensitivity analysis and during the model verification step, which supported the robustness of the assumed prior value.
Third, although quantitative BHB levels could be modelled and showed a clear exposure-response relation, DKA events could not be modelled because of low event numbers and an inability to model the precipitating factors (such as infections or pump malfunction) that appear to represent a component cause for DKA. 9 The HbA1c benefit and minor blood BHB level elevation from the low-dose empagliflozin 2.5 mg option that was directly observed in a phase 3 clinical trial was confirmed using two modelling approaches from independent studies.
